ArticleBMJ open2015
Epidemiology of HEV in the Mediterranean basin: 10-year prevalence in Italy.
Article in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- A systematic review and meta-analysis of predictors of human hepatitis E virus exposure in non-endemic countries.Zoonoses and public health · 2020Pooled it
- Hepatitis E virus infection prevalence among men who have sex with men involved in a hepatitis A virus outbreak in Italy.Blood transfusion = Trasfusione del sangue · 2019Trial
- Hepatitis A to E in People with HIV: A Virus-Specific Review of Prevention and Treatment.Infectious diseases and therapy · 2026Review
- Testing Hepatitis E Seroprevalence among HIV-Infected Patients in Greece: The SHIP Study.Pathogens (Basel, Switzerland) · 2024Article
- Virus-like particle vaccinology, from bench to bedside.Cellular & molecular immunology · 2022Review
- Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice.World journal of gastroenterology · 2022Review
- Clinical Characteristics of Acute Hepatitis E and Their Correlation with HEV Genotype 3 Subtypes in Italy.Pathogens (Basel, Switzerland) · 2020Article
- Molecular Characterization of HEV Genotype 3 in Italy at Human/Animal Interface.Frontiers in microbiology · 2020Article
- Hepatitis E 3ra Genotype Infection in People Living With HIV in Spain.Frontiers in microbiology · 2020Article
- Hepatitis E Infection in HIV-Infected Patients.Frontiers in microbiology · 2019Article
- Hepatitis E in Italy: 5 years of national epidemiological, virological and environmental surveillance, 2012 to 2016.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018Article
- Hiding in Plain Sight? It's Time to Investigate Other Possible Transmission Routes for Hepatitis E Virus (HEV) in Developed Countries.Food and environmental virology · 2018Review
- Hepatitis E virus infection in North Italy: high seroprevalence in swine herds and increased risk for swine workers.Epidemiology and infection · 2017Article
- Hepatitis E virus (HEV): seroprevalence and HEV RNA detection in subjects attending a sexually transmitted infection clinic in Brussels, Belgium.Epidemiology and infection · 2017Article
- Hepatitis E virus: Current epidemiology and vaccine.Human vaccines & immunotherapeutics · 2016Review
- Epidemiology of Hepatitis E Virus in European Countries.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe present study is aimed at describing the seroprevalence and exploring potential risk factor(s) for hepatitis E virus (HEV) in participants who voluntarily underwent anti-HIV antibody testing. STUDY
designSeroprevalence study.
settingThe HIV prevention unit at the National Institute for Infectious Diseases Lazzaro Spallanzani, serving as a referral centre for HIV infection in Lazio, an Italian Region with about 5.6 million inhabitants.
participantsParticipants are a random sample of all subjects who receive counselling and undergo serological tests for anti-HIV antibody (Ab) between 2002 and 2011. RISK FACTORS AND OUTCOME: A set of 16 epidemiological variables (risk factors) were assessed for association with positivity to anti-HEV IgG (outcome).
resultsBetween 2002 and 2011, 27,351 serum specimens and related epidemiological information were collected; of these 1116 were randomly selected and analysed. The overall anti-HEV IgG prevalence was 5.38% (60 out of 1116) with evidence of potential heterogeneity between years of sampling (p=0.055). Multivariate analysis provided evidence that anti-HEV IgG prevalence increases by 4% per year of participants' age (95% CI 1% to 7%, p=0.002). In addition, men who have sex with men and participants who were born outside Italy have an OR for past HEV infection that is about two times higher than in those who were not (p=0.040 and p=0.027, respectively). Analysis of temporal trend showed that variation of anti-HEV IgG can be well explained by a cubic logistic regression model, which describes the variation of prevalence over time as a fluctuation within a 3-year period (p=0.032).
conclusionsThis study provides new evidence that besides the orofecal and zoonotic routes, intimate contacts between males may be a significant mode of HEV transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.